Drug Trial Radar · NCT00230178
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 12, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Apr 2004
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 30, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multi-center, open-label, parallel group study with three arms: * Rasburicase alone * Rasburicase followed by Allopurinol * Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three arms.
Conditions
- Tumor Lysis Syndrome
- Cancer
- Hyperuricemia
Interventions
Rasburicase (SR29142)Drug
30-min IV infusion
AllopurinolDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Uric Acid ResponderTime frame: Day 3 through Day 7
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Alta Bates Comprehensive Cancer Center
Berkeley, California
UCLA Medical Center
Los Angeles, California
Rocky Mountain Cancer Center
Denver, Colorado
University of Florida Health Science Center at Jacksonville
Jacksonville, Florida
Ochsner Clinic Foundation
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
New York Methodist Hospital
Brooklyn, New York
Roswell Park Cancer Institute
Buffalo, New York
University of Rochester Medical Center
Rochester, New York
New York Medical College
Valhalla, New York
Duke University Medical Center
Durham, North Carolina
Oregon Health and Sciences University
Portland, Oregon
University of Pennsylvania Health Systems
Philadelphia, Pennsylvania
University of Texas MD Anderson Cancer Center
Houston, Texas
Mary Babb Randolph Cancer Center
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.